Helix BioPharma announces Q2 2006 financial results (Chronic Hepatitis C)

Helix BioPharma announces Q2 2006 financial results
[Press Release] CNW Group via Yahoo! Finance - Mar 14 2:00 PM
Helix BioPharma Corp. today announced financial results for the second quarter of fiscal 2006, ended January 31, 2006.Save to My Web

Human Genome Sciences Reports Positive Interim Results of Phase 2 Trial of Albuferon(TM) In Combination With Ribavirin
[Press Release] PR Newswire via Yahoo! Finance - Mar 14 5:01 AM
Human Genome Sciences, Inc. today reported the interim results of a Phase 2 clinical trial to evaluate the safety, tolerability and efficacy of Albuferon in combination with ribavirin in patients with chronic hepatitis C who failed to respond to previous interferon alpha-based treatment regimens.Save to My Web

SciClone's ZADAXIN Granted Orphan Drug Designation for Malignant Melanoma in United States
SYS-CON Media - Mar 20 8:29 AM
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)today announced that thymalfasin, the chemical composition of ZADAXIN ,has been granted Orphan Drug designation for the treatment of stage IIbthrough stage IV malignant melanoma by the U.S. Food and DrugAdministration (FDA). Orphan Drug designation could provide SciClone withseven years of market exclusivity in the United States should ZADAXINreceive Save to My Web

Advanced Biotherapy Signs Memorandum of Understanding with Battelle
[Press Release] Business Wire via Yahoo! Finance - Mar 22 6:30 AM
WOODLAND HILLS, Calif.----March 22, 2006--Advanced Biotherapy, Inc. today announced that it has entered into an initial Memorandum of Understanding with Battelle for the development and use of monoclonal antibodies to treat humans and animals exposed to anthrax and plague as well as autoimmune diseases.Save to My Web

Metabasis Comments on Positive 48 Week HBV Data From Pradefovir Mesylate Phase 2 Study Reported by Valeant
[Press Release] PR Newswire via Yahoo! Finance - Mar 16 5:45 AM
Metabasis Therapeutics Inc. commented today on the 48 week results from a Phase 2 study of pradefovir, an oral anti-viral product candidate it discovered and subsequently licensed to Valeant Pharmaceuticals International.Save to My Web